BioSpace News Archive

Vico Therapeutics B.V. announced a $60 million Series B financing.

Orion Corporation (“Orion”) and MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) have initiated two pivotal Phase 3 clinical trials evaluating ODM-208/MK5684, an investigational CYP11A1 inhibitor, in combination with hormone replacement therapy (HRT), for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.

Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.

EndoQuest™ Robotics, Inc. and OMNIVISION announced a partnership to integrate OMNIVISION’s OCHFA CameraCubeChip® into EndoQuest’s Flexible Robotic System.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 19,251 shares of its common stock to six new employees.

Dyne Therapeutics, Inc. diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET).

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.

Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of T2D and obesity, announced the nomination of RJVA-001 as the first clinical T2D candidate in its Rejuva gene therapy platform.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced business updates, its expected 2024 milestones and its upcoming presentation at the 42nd Annual J.P. Morgan Healthcare Conference.